Moonwalk Biosciences
PrivateLast Round
Series B
Sep 8, 2026
Est. Valuation
$150M
Total Funding Raised
$127M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Moonwalk Biosciences is a biotechnology company that develops precision epigenetic therapies by coupling an epigenetic discovery platform with precise engineering to reprogram cells to a healthy state.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Moonwalk Biosciences Comparables
Compare Moonwalk Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tune Therapeutics | 90% | |
| Chroma Medicine | 89% | |
| Epigenic Therapeutics | 88% |
Moonwalk Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 8, 2026 | ||||
| Series A | Jan 4, 2024 |
Key People
Founding team and executive leadership
Moonwalk Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Ventures | Series B, Series A |
| GV | Series A |
| Khosla Ventures | Series B, Series A |
| ARCH Venture Partners | Series B, Series A |
| YK Bioventures | Series B |
| ARCH Venture Partners | Series A |
| Alpha Wave Global | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2026
$70M round led by YK Bioventures and Alpha Wave Global.
- Jul 25, 2026
Monthly visitors increased 38% MoM, reaching 4.6K.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
Moonwalk Biosciences, Inc. hires Stephen Djedjos as senior vice president, clinical development.
- is_developingSep 8, 2026
Moonwalk Biosciences, Inc. is developing effective, safe and durable epigenetic medicines.
- is_developingSep 8, 2026
Moonwalk Biosciences, Inc. is developing siRNA medicines targeting adipose tissue.
- is_developingSep 8, 2026
Moonwalk Biosciences, Inc. is developing small interfering RNA therapeutics on Sep 8th '26.
- receives_financingSep 8, 2026
Moonwalk Biosciences, Inc. received financing of $70M in Series B on Sep 8th '26.
Moonwalk Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Moonwalk Biosciences's valuation, stock price, and market status.
Is Moonwalk Biosciences a public or private company?
Moonwalk Biosciences is a private company.
What is the current stock price of Moonwalk Biosciences?
Moonwalk Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is Moonwalk Biosciences worth (valuation)?
Valuation information for Moonwalk Biosciences is not publicly available.
Can I buy Moonwalk Biosciences stock?
Moonwalk Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Moonwalk Biosciences's last funding round?
Moonwalk Biosciences's most recent funding round was Series A on January 4, 2024.
Who are the main investors in Moonwalk Biosciences?
Key investors in Moonwalk Biosciences include Future Ventures, ARCH Venture Partners, Alpha Wave Global.
Will Moonwalk Biosciences IPO soon?
No public IPO plans have been announced for Moonwalk Biosciences.
How can I track Moonwalk Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Moonwalk Biosciences's secondary market activity and sign up for updates.